AbelZeta Inc.

Johnson & Johnson's Dual-Targeting CAR-T Therapy Achieves 80% Complete Response Rate in Lymphoma Trial

- Johnson & Johnson's investigational dual-targeting CAR-T therapy JNJ-4496 demonstrated 75-80% complete response rates in patients with relapsed or refractory large B-cell lymphoma at the recommended Phase 2 dose. - The therapy targets both CD19 and CD20 antigens on malignant B-cells, potentially addressing resistance mechanisms that limit current single-antigen CAR-T treatments to 40% long-term remission rates. - Safety data showed no Grade 3 or 4 cytokine release syndrome cases, with neutropenia being the most common severe adverse event affecting 72% of patients. - The Phase 1b study results were presented at the 2025 European Hematology Association Congress, marking a significant advancement in treating the most common aggressive lymphoma type.